Background: Sunitinib (SU11248) is an oral multi-target tyrosine kinase inhibitor (TKI) with
low molecular weight, that inhibits platelet-derived growth factor receptors (PDGF-Rs) and …

Objective Our objective was to evaluate the efficacy and safety of sunitinib following at least
one course of radioactive iodine treatment in patients with advanced differentiated thyroid …

Purpose Patients with advanced radioactive iodine resistant differentiated (MDTC) or
medullary (MMTC) thyroid cancer had an unmet need. Early data showed promising efficacy …

6058 Background: There is no standard treatment for advanced thyroid cancer refractory to
radioactive iodine (RTC). There are arguments for implication of angiogenesis in TC …

The limited therapeutic options available for patients with metastatic papillary thyroid
carcinomas (PTC) and follicular thyroid carcinomas (FTC) necessitates the development of …

6025 Background: Few treatment options exist for patients with refractory differentiated
(including papillary, follicular, and Hurthle cell) and medullary thyroid cancers (DTC and …

Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate Results of Phase
II THYSU Page 1 Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate …

Purpose Sunitinib, an oral multitargeted tyrosine kinase inhibitor that inhibits VEGFR,
PDGFR, FLT3, KIT, and RET, is currently approved for the treatment of imatinib-refractory …

Background: Sunitinib malate (Sutent®, Pfizer, Inc.; SU11248) is a selective, multitargeted
inhibitor of receptor tyrosine kinases and has been shown to inhibit receptors for VEGF …

6062 Background: There is no standard treatment for metastatic, iodine-refractory, WDTC or
MTC. Thyroid carcinomas are highly vascular tumors, providing a rationale for trials of …